The Experts below are selected from a list of 240 Experts worldwide ranked by ideXlab platform
Robert R Edelman - One of the best experts on this subject based on the ideXlab platform.
-
Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280]
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
erratum to Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum vaccine 21 2003 269 280
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum sporozoites
Vaccine, 2002Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, B J SchmeckpeperAbstract:We tested the clinical reactions to a synthetic, Plasmodium falciparum, circumsporozoite multiple antigen peptide (MAP) vaccine in 39 volunteers immunized two to three times over 2–8 months using a dose escalation design. Immediate pain at the injection site was associated with the adjuvant QS-21 (P<0.001), and delayed local inflammatory reactions were associated with high-titered circulating IgG anti-MAP antibody (P=0.03). Because two volunteers developed acute, systemic urticaria after the third immunization associated with development of serum IgE MAP antibody, we employed Immediate-Type Hypersensitivity skin tests (ITH-STs) using intradermal injections of diluted MAP vaccine to identify persons sensitized to the vaccine. ITH-STs were negative in seven volunteers tested 27 days after the first vaccination, but six of these individuals developed positive wheal and flare reactions when tested 14 or 83 days after the second vaccination; IgE MAP antibody was detected in only one of them. Another cohort of 16 volunteers, including the 2 allergic individuals, were ITH-ST negative when first tested late after their second or third vaccination at 6–7 months. Five of five non-immunized persons were also ITH-ST negative. ITH-STs may help identify individuals sensitized to malaria peptides and at potential risk of developing systemic allergic reactions after re-vaccination.
Barbara J Schrneckpeper - One of the best experts on this subject based on the ideXlab platform.
-
erratum to Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum vaccine 21 2003 269 280
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280]
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Sacared A Bodison - One of the best experts on this subject based on the ideXlab platform.
-
Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280]
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
erratum to Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum vaccine 21 2003 269 280
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum sporozoites
Vaccine, 2002Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, B J SchmeckpeperAbstract:We tested the clinical reactions to a synthetic, Plasmodium falciparum, circumsporozoite multiple antigen peptide (MAP) vaccine in 39 volunteers immunized two to three times over 2–8 months using a dose escalation design. Immediate pain at the injection site was associated with the adjuvant QS-21 (P<0.001), and delayed local inflammatory reactions were associated with high-titered circulating IgG anti-MAP antibody (P=0.03). Because two volunteers developed acute, systemic urticaria after the third immunization associated with development of serum IgE MAP antibody, we employed Immediate-Type Hypersensitivity skin tests (ITH-STs) using intradermal injections of diluted MAP vaccine to identify persons sensitized to the vaccine. ITH-STs were negative in seven volunteers tested 27 days after the first vaccination, but six of these individuals developed positive wheal and flare reactions when tested 14 or 83 days after the second vaccination; IgE MAP antibody was detected in only one of them. Another cohort of 16 volunteers, including the 2 allergic individuals, were ITH-ST negative when first tested late after their second or third vaccination at 6–7 months. Five of five non-immunized persons were also ITH-ST negative. ITH-STs may help identify individuals sensitized to malaria peptides and at potential risk of developing systemic allergic reactions after re-vaccination.
Oscar Kashala - One of the best experts on this subject based on the ideXlab platform.
-
Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280]
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
erratum to Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum vaccine 21 2003 269 280
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum sporozoites
Vaccine, 2002Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, B J SchmeckpeperAbstract:We tested the clinical reactions to a synthetic, Plasmodium falciparum, circumsporozoite multiple antigen peptide (MAP) vaccine in 39 volunteers immunized two to three times over 2–8 months using a dose escalation design. Immediate pain at the injection site was associated with the adjuvant QS-21 (P<0.001), and delayed local inflammatory reactions were associated with high-titered circulating IgG anti-MAP antibody (P=0.03). Because two volunteers developed acute, systemic urticaria after the third immunization associated with development of serum IgE MAP antibody, we employed Immediate-Type Hypersensitivity skin tests (ITH-STs) using intradermal injections of diluted MAP vaccine to identify persons sensitized to the vaccine. ITH-STs were negative in seven volunteers tested 27 days after the first vaccination, but six of these individuals developed positive wheal and flare reactions when tested 14 or 83 days after the second vaccination; IgE MAP antibody was detected in only one of them. Another cohort of 16 volunteers, including the 2 allergic individuals, were ITH-ST negative when first tested late after their second or third vaccination at 6–7 months. Five of five non-immunized persons were also ITH-ST negative. ITH-STs may help identify individuals sensitized to malaria peptides and at potential risk of developing systemic allergic reactions after re-vaccination.
Carter L Diggs - One of the best experts on this subject based on the ideXlab platform.
-
Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280]
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
erratum to Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum vaccine 21 2003 269 280
Vaccine, 2003Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, Barbara J SchrneckpeperAbstract:Erratum to “Immediate-Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum” [Vaccine 21 (2003) 269–280] Robert Edelman a,∗, Steven S. Wasserman a, James G. Kublin a, Sacared A. Bodison b, Elizabeth H. Nardin c, Giane A. Oliveira c, Sobia Ansari c, Carter L. Diggs d, Oscar L. Kashala e, Barbara J. Schrneckpeper f, Robert G. Hamilton g a Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA b University Health Center, University of Maryland, College Park, MD, USA c Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY, USA d Malaria Vaccine Development Program, Agency for International Development, Washington, DC, USA e Aquila Biopharmaceuticals Inc., Framingham, MA, USA f Immunogenetics Laboratories, Johns Hopkins University School of Medicine, Baltimore, MD, USA g Reference Laboratory for Dermatology, Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
-
Immediate Type Hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi antigen peptide vaccine pfcs map1nyu against plasmodium falciparum sporozoites
Vaccine, 2002Co-Authors: Robert R Edelman, Steven S Wasserman, James G Kublin, Sacared A Bodison, Elizabeth Nardin, Giane A Oliveira, Sobia Ansari, Carter L Diggs, Oscar Kashala, B J SchmeckpeperAbstract:We tested the clinical reactions to a synthetic, Plasmodium falciparum, circumsporozoite multiple antigen peptide (MAP) vaccine in 39 volunteers immunized two to three times over 2–8 months using a dose escalation design. Immediate pain at the injection site was associated with the adjuvant QS-21 (P<0.001), and delayed local inflammatory reactions were associated with high-titered circulating IgG anti-MAP antibody (P=0.03). Because two volunteers developed acute, systemic urticaria after the third immunization associated with development of serum IgE MAP antibody, we employed Immediate-Type Hypersensitivity skin tests (ITH-STs) using intradermal injections of diluted MAP vaccine to identify persons sensitized to the vaccine. ITH-STs were negative in seven volunteers tested 27 days after the first vaccination, but six of these individuals developed positive wheal and flare reactions when tested 14 or 83 days after the second vaccination; IgE MAP antibody was detected in only one of them. Another cohort of 16 volunteers, including the 2 allergic individuals, were ITH-ST negative when first tested late after their second or third vaccination at 6–7 months. Five of five non-immunized persons were also ITH-ST negative. ITH-STs may help identify individuals sensitized to malaria peptides and at potential risk of developing systemic allergic reactions after re-vaccination.
